Bristol-Myers Squibb Co (LIM:BMY) Stock Based Compensation: $555 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LIM:BMY Bristol-Myers Squibb Co LIM:BMY
57 GF Score
Price $56.98
GF Value $48.22
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co Stock Based Compensation?

Bristol-Myers Squibb Co LIM:BMY 57 Stock Based Compensation is $555 Mil as of Mar. 2026. GuruFocus rates LIM:BMY with a GF Score™ of 57/100 and a GF Value™ of $48.22 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Bristol-Myers Squibb Co's Stock Based Compensation for the three months ended in Mar. 2026 was $146 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $555 Mil.

Bristol-Myers Squibb Co Stock Based Compensation Related Terms

Bristol-Myers Squibb Co Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Bristol-Myers Squibb Co's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co Stock Based Compensation Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 583.00 457.00 518.00 507.00 553.00

Bristol-Myers Squibb Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 144.00 137.00 139.00 133.00 146.00
LIM:BMY
57GF Score
Bristol-Myers Squibb Co LIM:BMY
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bristol-Myers Squibb Co Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $555 Mil.

What does a Stock Based Compensation of $555 Mil mean?
Bristol-Myers Squibb Co (LIM:BMY) has a Stock Based Compensation of $555 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Bristol-Myers Squibb Co and its competitors.
Is Bristol-Myers Squibb Co's Stock Based Compensation too high?
Bristol-Myers Squibb Co's current Stock Based Compensation is $555 Mil. Overall, Bristol-Myers Squibb Co has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Stock Based Compensation compare to PFE and GILD?
Bristol-Myers Squibb Co's Stock Based Compensation of $555 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Bristol-Myers Squibb Co and its competitors. Bristol-Myers Squibb Co's current Stock Based Compensation is $555 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (LIM:BMY) is currently considered Modestly Overvalued. The stock's GF Value™ is $48.22, compared to a current price of $56.98 — trading 18.2% above its estimated fair value. The current Stock Based Compensation is $555 Mil. Bristol-Myers Squibb Co's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Bristol-Myers Squibb Co (LIM:BMY), the current Stock Based Compensation is $555 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bristol-Myers Squibb Co (LIM:BMY) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of $56.98 is trading 18.2% above its estimated GF Value™ of $48.22. GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.

Key valuation signals for LIM:BMY:

  • Stock Based Compensation: $555 Mil
  • GF Value™: $48.22 vs. price of $56.98 (18.2% above fair value)
  • GF Score™: 57/100 with 6 warning signs

No single metric tells the full story. See the LIM:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
57GF Score

Get the complete analysis for LIM:BMY

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$56.98
Price
$48.22
GF Value